Sex Differences in Comorbidity, Therapy, and Health Services' Use of Heart Failure in Spain: Evidence from Real-World Data by Gracia Gutiérrez, Anyuli et al.




Sex Differences in Comorbidity, Therapy, and Health
Services’ Use of Heart Failure in Spain: Evidence
from Real-World Data
Anyuli Gracia Gutiérrez 1, Beatriz Poblador-Plou 2, Alexandra Prados-Torres 2 ,
Fernando J Ruiz Laiglesia 3,† and Antonio Gimeno-Miguel 2,*,†
1 Research Group on Heart Failure, IIS Aragón, Internal Medicine Service, Hospital General de la Defensa,
50009 Zaragoza, Spain; agraciagut@gmail.com
2 EpiChron Research Group, Aragon Health Sciences Institute (IACS), IIS Aragón, REDISSEC,
Miguel Servet University Hospital, 50009 Zaragoza, Spain; bpoblador.iacs@aragon.es (B.P.-P.);
sprados.iacs@aragon.es (A.P.-T.)
3 Research Group on Heart Failure, Faculty of Medicine, Internal Medicine Service,
Lozano Blesa University Hospital, 50009 Zaragoza, Spain; fruizl@unizar.es
* Correspondence: agimenomi.iacs@aragon.es; Tel.: +34-976-765-500 (ext. 5375)
† These authors contributed equally to this work and served as senior co-authors.
Received: 29 February 2020; Accepted: 20 March 2020; Published: 23 March 2020


Abstract: Heart failure (HF) is becoming increasingly prevalent and affects both men and women.
However, women have traditionally been underrepresented in HF clinical trials. In this study, we
aimed to analyze sex differences in the comorbidity, therapy, and health services’ use of HF patients.
We conducted a cross-sectional study in Aragón (Spain) and described the characteristics of 17,516
patients with HF. Women were more frequent (57.4 vs. 42.6%, p < 0.001) and older (83 vs. 80 years,
p < 0.001) than men, and presented a 33% lower risk of 1-year mortality (p < 0.001). Both sexes showed
similar disease burdens, and 80% suffered six or more diseases. Some comorbidities were clearly
sex-specific, such as arthritis, depression, and hypothyroidism in women, and arrhythmias, ischemic
heart disease, and COPD in men. Men were more frequently anti-aggregated and anti-coagulated and
received more angiotensin-converting-enzyme (ACE) inhibitors and beta-blockers, whereas women
had more angiotensin II antagonists, antiinflammatories, antidepressants, and thyroid hormones
dispensed. Men were admitted to specialists (79.0 vs. 70.6%, p < 0.001), hospital (47.0 vs. 38.1%,
p < 0.001), and emergency services (57.6 vs. 52.7%, p < 0.001) more frequently than women. Our
results highlight the need to conduct future studies to confirm the existence of these differences and
of developing separate HF management guidelines for men and women that take into account their
sex-specific comorbidity.
Keywords: Heart failure; epidemiology; comorbidity; medication; health services use; sex; gender
1. Introduction
Heart failure (HF) is a complex clinical syndrome characterized by the reduced ability of the heart
to pump and/or fill with blood [1]. This condition is becoming increasingly prevalent and currently
affects around 26 million people, challenging health systems worldwide [2].
Sex differences in the epidemiology, comorbidity, pharmacological treatment, and management of
HF have been highlighted [3–9]. Although HF incidence is initially higher in men, women survive
longer after the onset of the disease and, as one’s age advances, its prevalence becomes higher in
women compared to men [8]. Subsequently, the total number of patients affected by HF in the general
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population is similar in both sexes, or even higher in women [7]. Yet, women have traditionally been
underrepresented in HF clinical trials and cardiovascular guidelines [10].
Heart failure presents, in most cases, as a chronic disease with a high burden of comorbidities,
some of which seem to be sex-specific [6]. Whereas women are more likely to present comorbid
hypertension, diabetes, hypothyroidism, obesity, and depression, men tend to have more peripheral
vascular disease, ischemic heart disease and chronic obstructive pulmonary disease (COPD) [9,11,12].
The overall constellation of comorbidities surrounding HF may play an important role not only in the
pathophysiology, but also in the treatment and prognosis of the disease [13].
Some differences in the response to treatment between men and women with HF might respond to
specificities of their comorbidity pattern and of the pathophysiological origin of the disease. However,
others might represent non-justified, gender-related differences [14]. On the other hand, due to the
paucity of women recruited to HF trials, they show worse compliance with clinical practice guidelines,
which are predominantly based on male-derived data. Women also receive lower average drug doses
and show more adverse effects and worse prognoses in certain types of HF [4,9,15]. Similarly, care
processes, resource use, and quality of care of HF patients may be different depending on their sex [16].
There is an unmet need of assessing whether sex differences in comorbidities of HF require
specific management strategies. More studies focusing on women aimed at optimizing sex-specific
therapy and, therefore, improving clinical outcomes in women, are needed [17]. Moreover, it has been
suggested that HF may be a systemic, rather than a cardiac disorder, also involving other systems,
such as the vascular, pulmonary, renal, gastrointestinal, and hepatic systems [18]. The identification of
different comorbidity pathways in HF could provide evidence for individualized, person-centered
care, targeting specific comorbidities and symptoms [19].
Combined efforts from different stakeholders (e.g., researchers, health authorities, and registry
administrators) are required to adequately fill our knowledge gap on sex differences in HF [11].
In this context, the increasing availability for research of real-world, routinely collected health data
obtained during the care process (e.g., electronic health records–EHRs) represents a unique opportunity
to conduct clinical-epidemiological, large-scale population studies and provide us with real-world
evidence on sex differences in HF.
The aim of this work was to describe the demographic, clinical, and health services’ use
characteristics of a Spanish cohort of 17,516 men and women with HF based on real-world data, with a
focus on the identification of sex differences.
2. Materials and Methods
We conducted a cross-sectional, observational study in the EpiChron Cohort, which links the
information on demographics, diagnoses, drugs dispensed, and healthcare use rates of all public health
system users in the Spanish region of Aragón. This cohort was conformed in 2011 including 1.25 million
people at baseline (approximately 95% of the total inhabitants of the region). A description of the cohort
and of the data sources was published elsewhere [20]. We selected for this study all prevalent patients
with a diagnosis of HF in their primary or hospital EHRs on 1 January 2015 (i.e., 17,516 patients),
and analyzed their demographic and clinical information corresponding to the year of study.
The Clinical Research Ethics Committee of Aragón (CEICA) approved the research protocol of this
study (PI18/082), which complies with the Declaration of Helsinki. The CEICA waived the requirement
to obtain informed consent from patients since all the information used was anonymized.
For each patient, we analyzed demographic data (i.e., age, sex, area of residence, acquisitive
level, immigration status), all chronic condition diagnoses from primary and/or hospital care, all
chronic medications dispensed, including those specifically used for the treatment of HF, monthly
pharmacy expenditure, health services utilization (i.e., visits to primary care, specialties, hospital,
and emergency department), self-reported data on drinking and smoking behaviors, and all-cause
mortality. To determine the acquisitive level of each patient, we used the information regarding their
type/degree of copayment of drugs covered by the public health system as a proxy variable to estimate
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patients’ individual annual income, which was divided into three categories as below 18,000 € (A),
between 18,000 and 100,000 € (B), or above 100,000 €.
Diagnoses were extracted from the EHRs of both primary and hospital care levels, and
included all active episodes between 1 January 2015 and 31 December 2015, even if a healthcare
professional had recorded them before the initial date. Diseases were originally coded according to
the International Classification of Primary Care (ICPC) or the International Classification of Diseases,
Ninth Revision, Clinical Modification (ICD-9-CM), and subsequently grouped into 260 mutually
exclusive Expanded Diagnostic Clusters (EDCs) using the Johns Hopkins ACG® System (version 11.0,
The Johns Hopkins University, Baltimore, MD, USA) [21]. We included every patient with the
CAR05 EDC code, and considered for the analysis all 114 possible EDCs previously established as
chronic by Salisbury et al. [22]. We defined multimorbidity as the presence of two or more EDCs from
Salisbury’s list.
Chronic medications were defined as those with three or more dispensations over the 365-day
follow-up period, using the Anatomical-Therapeutic-Chemical (ATC) classification system code at the
third level. We defined polypharmacy as the simultaneous use of five or more drugs.
We performed a descriptive analysis of demographic, clinical, drug use, and health services use
information of the population with HF based on their sex. The results were expressed as means, medians,
and/or frequencies, accompanied by their corresponding standard deviations and/or interquartile
ranges (IR). We compared age-adjusted means, medians, and frequencies using Student’s t-test, the
Mann–Whitney U test, and chi-squared test, respectively. We also performed a multivariate Cox
regression survival analysis to assess the effect of sex on 1-year mortality risk, after adjusting the
hazard ratio (HR) by the age and number of comorbidities.
All statistical analyses were conducted using STATA (Version 12.0, StataCorp LLC, College Station,
TX, USA). Statistical significance was set at p < 0.05.
3. Results
3.1. Overall Demographic and Clinical Characteristics
The majority of patients with HF in our cohort were women (57.4% vs. 42.6%, p < 0.001), who
were, on average, older than men (Table 1). Although HF was more frequent in men in the population
under 65 years, this condition was much more frequent in women over 65 years compared to their
male counterparts, especially in the population over 85 years. No differences between men and women
were shown in their immigrant status, area of residence, or acquisitive level. Women presented a
slightly, although significant, higher body mass index (BMI) compared to men (30.3 vs. 29.6, p < 0.001),
whereas men self-reported higher prevalence (%) of toxic habits, such as alcohol intake (26.2 vs. 3.0,
p < 0.001) and smoking (12.4 vs. 3.5, p < 0.001).
Men and women with HF presented a similar disease burden, with 99 in 100 patients presenting
multimorbidity, and 80% of them with six or more chronic conditions. The burden of drugs dispensed
was also similar between sexes, with more than 80% of patients having polypharmacy. Men incurred,
however, greater monthly pharmacy expenditure compared to women (1015 € vs. 821 €, p < 0.001).
3.2. Sex Differences in Comorbidity of HF
Both men and women showed a high comorbidity burden accompanying HF (Table 2).
Hypertension (73%) and lipid metabolism disorders (45%) were the two most frequent chronic
conditions in both men and women. Even after adjusting prevalence by age, some chronic conditions
were clearly more frequent in women compared to men, such as (%) depression (29.0 vs. 13.0, p < 0.001),
osteoporosis (26.2 vs. 4.5, p < 0.001), arthritis (42.0 vs. 27.5, p < 0.001), varicose veins (36.3 vs. 14.8,
p < 0.001), hypothyroidism and other endocrine disorders (28.2 vs. 14.2, p < 0.001), and asthma
(13.1 vs. 6.0, p < 0.001), among others. On the other hand, conditions such as COPD (32.3 vs. 14.0,
p < 0.001), ischemic heart disease and acute myocardial infarction (39.9 vs. 22.1, p < 0.001), cardiac
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arrhythmia (44.5 vs. 37.0, p < 0.001), chronic renal failure (13.9 vs. 8.6, p < 0.001), gout (14.3 vs. 3.7,
p < 0.001), behaviors problems (12.1 vs. 3.9, p < 0.001), cardiomyopathy (4.9 vs. 2.2, p < 0.001), and
peripheral vascular disease (4.3 vs. 1.7, p < 0.001) were much more frequent in men. A much larger
number of comorbidities showed sex differences in their prevalence (Table 2; Table S1), although not as
clinically relevant as those mentioned above.
Table 1. Demographic and clinical description of the study population with heart failure based on
their sex.
Characteristics Men Women p Value
N (%) 7454 (42.6%) 10,062 (57.4%) <0.001
Age
Median (IR a) 80 (15) 83 (11) <0.001
Age interval, years (n, %) <0.001
≤44 281 (1.6%) 223 (1.3%)
45–64 886 (5.1%) 572 (3.3%)
65–84 4146 (23.7%) 4837 (27.6%)
≥85 2141 (12.2%) 4430 (25.3%)
Immigrant (n, %) 83 (1.1%) 122 (1.2%) 0.595
Residence, rural (n, %) 3575 (48.0%) 4444 (44.2%) 0.981
Acquisitive level b (n, %) 0.060
A 474 (6.4%) 732 (7.3%)
B 6917 (92.8%) 9245 (91.9%)
C 63 (0.8%) 84 (0.8%)
BMI c (median, IR) 29.6 (6.04) 30.3 (7.83) <0.001
Toxic habits d (n, %)
Alcohol consumption, yes 1954 (26.2%) 300 (3.0%) <0.001
Smoking, yes 924 (12.4%) 349 (3.5%) <0.001
Chronic diseases e
Median (IR) 9 (6) 9 (6) 0.910
Number of diseases (n, %) 0.307
1 84 (1.1%) 95 (0.9%)
2 153 (2.1%) 186 (1.8%)
3 262 (3.5%) 337 (3.3%)
4 423 (5.7%) 544 (5.4%)
5 569 (7.6%) 713 (7.1%)
≥6 5962 (80%) 8187 (81.4%)
Multimorbidity f (n, %) 7370 (98.9%) 9967 (99.1%) 0.234
Drugs dispensed g
Median (IR) 8 (5) 8 (5) 0.385
Number of drugs (n, %) 0.258
0–1 227 (3.7%) 348 (4.1%)
2–4 707 (11.5%) 1002 (11.9%)
≥5 5209 (84.8%) 7043 (83.9%)
Monthly pharmacy expenditure, € (median, IR) h 1015 (−1237) 821 (−1111) <0.001
a Interquartile range; b Proxy variable of acquisitive level of patients according to their annual individual income:
below 18,000 € (A), between 18,000 and 100,000 € (B), or above 100,000 € (C); c Body mass index; d Self-reported by
the patient and retrieved from patient’s general descriptors; e From a list of 114 chronic conditions including HF,
age-adjusted means are presented; f Defined as the presence of two or more chronic conditions, HF included; g Using
the Anatomical-Therapeutic-Chemical classification code at the third level, age-adjusted means are presented;
h Calculated with the retail price of each drug.
Int. J. Environ. Res. Public Health 2020, 17, 2136 5 of 13
Table 2. Differences in the comorbidity profile of men (n = 7454) and women (n = 10,062) with heart
failure. Age-adjusted prevalence of chronic comorbidities with a mean prevalence higher than 5%
is presented.
Chronic Condition a Men (n, %) Women (n, %) p Value
Hypertension 5292 (71.0) 7476 (74.3) <0.001
Disorders of lipid metabolism 3280 (44.0) 4629 (46.0) 0.009
Cardiac arrhythmia 3317 (44.5) 3723 (37.0) <0.001
Arthritis 2050 (27.5) 4226 (42.0) <0.001
Diabetes 2661 (35.7) 3210 (31.9) <0.001
Hematologic disorders, other 2177 (29.2) 2666 (26.5) <0.001
Cataract, aphakia 1968 (26.4) 2848 (28.3) 0.008
Varicose veins of lower extremities 1103 (14.8) 3653 (36.3) <0.001
Emphysema, chronic bronchitis, COPD b 2408 (32.3) 1409 (14.0) <0.001
Cardiovascular disorders, other 1811 (24.3) 2194 (21.8) <0.001
Obesity 1498 (20.1) 2616 (26.0) <0.001
Musculoskeletal disorders, other 1319 (17.7) 2485 (24.7) <0.001
Depression 969 (13.0) 2918 (29.0) <0.001
Ischemic heart disease (excluding AMI c) 1804 (24.2) 1560 (15.5) <0.001
Iron deficiency, other deficiency anemias 1394 (18.7) 1992 (19.8) 0.055
Musculoskeletal signs and symptoms 1290 (17.3) 1922 (19.1) 0.002
Cerebrovascular disease 1304 (17.5) 1690 (16.8) 0.216
Cardiac valve disorders 1275 (17.1) 1721 (17.1) 0.999
Surgical aftercare 1357 (18.2) 1469 (14.6) <0.001
Sleep disorders of nonorganic origin 1118 (15.0) 1741 (17.3) <0.001
Osteoporosis 335 (4.5) 2636 (26.2) <0.001
Respiratory signs and symptoms 1230 (16.5) 1378 (13.7) <0.001
Respiratory disorders, other 1275 (17.1) 1238 (12.3) <0.001
Dermatitis and eczema 1006 (13.5) 1248 (12.4) 0.036
Chronic ulcer of the skin 894 (12.0) 1378 (13.7) <0.001
Deafness, hearing loss 932 (12.5) 1298 (12.9) 0.521
Glaucoma 894 (12.0) 1248 (12.4) 0.412
Chronic renal failure 1036 (13.9) 865 (8.6) <0.001
Acute myocardial infarction 1170 (15.7) 664 (6.6) <0.001
Other endocrine disorders 596 (8.0) 1409 (14.0) <0.001
Hypothyroidism 462 (6.2) 1489 (14.8) <0.001
Neurologic disorders, other 671 (9.0) 1127 (11.2) <0.001
Asthma 447 (6.0) 1318 (13.1) <0.001
Gout 1066 (14.3) 372 (3.7) <0.001
Cardiovascular signs and symptoms 678 (9.1) 855 (8.5) 0.176
Behaviour problems 902 (12.1) 392 (3.9) <0.001
Blindness 574 (7.7) 815 (8.1) 0.304
Thrombophlebitis 455 (6.1) 885 (8.8) <0.001
Diverticular disease of colon 499 (6.7) 735 (7.3) 0.117
Low back pain 514 (6.9) 674 (6.7) 0.515
Neurologic signs and symptoms 432 (5.8) 724 (7.2) <0.001
Acute renal failure 574 (7.7) 463 (4.6) <0.001
Conjunctivitis, keratitis 410 (5.5) 644 (6.4) 0.013
Allergic rhinitis 447 (6.0) 574 (5.7) 0.302
Psychological signs and symptoms 321 (4.3) 624 (6.2) <0.001
Substance use 239 (3.2) 694 (6.9) <0.001
a From a list of 114 chronic conditions, listed in descending order of mean prevalence; b Chronic obstructive
pulmonary disease; c Acute myocardial infarction.
3.3. Pharmacology of HF
Drugs dispensed in the study population with HF are presented in Table 3. Sulphonamides
diuretics were the most frequently dispensed medications for HF in both men (73.6%) and women
(70.4%). The drugs recommended by clinical guidelines on HF were less frequently dispensed in women
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compared to men, such as beta-blocking agents (BB, 30.8% vs. 33.6%, p < 0.001), angiotensin-converting
enzyme (ACE) inhibitors (25.8% vs. 33.1%, p < 0.001), and aldosterone antagonists (23.7% vs. 28.7%,
p < 0.001), with the exception of angiotensin II receptor blockers (ARB, 23.8% vs. 21.0%, p < 0.001).
The joint dispensing of ACE inhibitors, ARB, BB, and aldosterone antagonists was more frequent in
men compared to women (8.4% vs. 6.1%, p < 0.001). Men also received more anti-aggregation (45.4%
vs. 34.4%, p < 0.001) and anti-coagulation treatments with vitamin K antagonists (38.6% vs. 33.2%,
p < 0.001) than women did.
Table 3. Differences in drug dispensation between men (n = 7454) and women (n = 10,062) with heart
failure. Age-adjusted dispensation rates of drugs of interest are shown.
Medication Men (n, %) Women (n, %) p Value
Anticoagulants
Vitamin K antagonists 2877 (38.6) 3341 (33.2) <0.001
Direct thrombin inhibitors 142 (1.9) 161 (1.6) 0.237
Direct factor Xa inhibitors 298 (4.0) 392 (3.9) 0.689
Antiplatelet
Platelet aggregation inhibitors excl. heparin 3384 (45.4) 3461 (34.4) <0.001
Diuretics
Thiazides, plain 127 (1.7) 171 (1.7) 0.867
Sulphonamides, plain 5486 (73.6) 7084 (70.4) <0.001
Aldosterone antagonists 2139 (28.7) 2385 (23.7) <0.001
Beta-blockers (BB)
BB, non-selective 52 (0.7) 111 (1.1) 0.004
BB, selective 2505 (33.6) 3099 (30.8) <0.001
Alpha and beta blocking agents 716 (9.6) 694 (6.9) <0.001
Calcium antagonists
Dihydropyridine derivatives 1200 (16.1) 1419 (14.1) <0.001
Phenylalkylamine derivatives 52 (0.7) 121 (1.2) 0.003
Benzothiazepine derivatives 790 (10.6) 1078 (10.7) 0.829
Digitalis glycosides 1334 (17.9) 1962 (19.5) 0.006
ACE a inhibitors/ARB b
ACE inhibitors, plain 2467 (33.1) 2596 (25.8) <0.001
ARB, plain 1565 (21.0) 2395 (23.8) <0.001
Lipid modifying agents, plain 3541 (47.5) 4246 (42.2) <0.001
Anti-inflammatory and antirheumatic products,
non-steroids 1998 (26.8) 3170 (31.5) <0.001
Glucocorticoids 1290 (17.3) 1519 (15.1) <0.001
Thyroid hormones 343 (4.6) 1288 (12.8) <0.001
Antidepressants 1416 (19.0) 3642 (36.2) <0.001
Inhaled therapy
Adrenergics, inhalants 2408 (32.3) 2415 (24.0) <0.001
Anticholinergics 1968 (26.4) 1389 (13.8) <0.001
a Angiotensin converting enzyme; b Angiotensin II receptor blockers.
Regarding the treatment of additional comorbidities, men were more frequently prescribed
with drugs related to the treatment of respiratory diseases, such as inhaled adrenergic agents
(32.3% vs. 24.0%, p < 0.001), anticholinergic agents (26.4% vs. 13.8%, p < 0.001), and corticosteroids for
systemic use (17.3% vs. 15.1%, p < 0.001). On the other hand, non-steroidal anti-inflammatory and
anti-rheumatic products (31.5% vs. 26.8%, p < 0.001), antidepressants (36.2% vs. 19.0%, p < 0.001), and
thyroid hormones (12.8% vs. 4.6%, p < 0.001) were more frequently dispensed in women.
3.4. Health Services Use and Prognosis
The number of HF patients with at least one visit to the general practitioner (GP) was slightly
higher in women than in men, although the number of annual visits (14.8 visits on average) was similar
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in both sexes (Table 4). Around 88% of patients with HF of both sexes visited nurses; however, women
showed a more intensive use of this service (19.9 vs. 13.6 visits, p = 0.011).
Table 4. Differences in the pattern of utilization of health services in men (n = 7454) and women
(n = 10,062) with heart failure during the year of study. Age-adjusted healthcare use rates are shown.
Health Services Use Men Women p Value
Primary care
Patients with at least 1 visit to GP a (n, %) 6917 (92.8) 9478 (94.2) <0.001
Number of visits to GP (mean, sd b) 14.7 (12.3) 14.9 (12.1) 0.343
Patients with at least 1 visit to nursing (n, %) 6552 (87.9) 8855 (88.0) 0.838
Number of visits to nursing (mean, sd) 13.6 (18.4) 19.9 (16.9) 0.011
Specialist care
Patients with at least 1 visit to any specialist (n, %) 5889 (79.0) 7104 (70.6) <0.001
Number of visits to specialties (mean, sd) 8.51 (10.5) 6.83 (9.1) <0.001
Number of different specialists visited (n, %) <0.001
1 1014 (13.6) 1499 (14.9)
2 1140 (15.3) 1469 (14.6)
3 1051 (14.1) 1258 (12.5)
4 850 (11.4) 986 (9.8)
5 678 (9.1) 704 (7.0)
≥6 1155 (15.5) 1197 (11.9)
Mean (sd) 2.90 (2.48) 2.41 (2.40) <0.001
Hospital care
Patients with at least 1 hospital admission (n, %) 3503 (47.0) 3834 (38.1) <0.001
Number of hospital admissions (mean, sd) 0.87 (1.31) 0.65 (1.10) <0.001
Length of stay, days (mean, sd) 8.25 (15.5) 6.39 (13.22) <0.001
Number of readmissions (mean, sd) 0.19 (0.60) 0.16 (0.52) <0.001
Emergency care
Patients with at least 1 visit to emergency room (n, %) 4294 (57.6) 5303 (52.7) <0.001
Number of visits (mean, sd) 1.32 (1.93) 1.15 (1.70) <0.001
a General Practitioner; b standard deviation.
On the other hand, a greater proportion of men than women used specialist care (79.0% vs. 70.6%,
p < 0.001), and men had almost two more visits than women did. The number of different specialists
visited was also greater in men compared to women (2.90 vs. 2.41, p < 0.001). Men also showed a
greater hospitalization rate (47.0% vs. 38.1%, p < 0.001) and higher number of hospital admissions
(0.87 vs. 0.65, p < 0.001), which were, on average, two days longer. The number of re-admissions to
hospital during the 1-year follow-up period was also slightly higher in men compared to women.
Regarding emergency care, men showed a greater utilization of this service compared to women
(57.6% vs. 52.7%, p < 0.001), and more visits to the emergency room (1.32 vs. 1.15 visits, p < 0.001).
The Cox regression survival analysis revealed that women presented a 33% (HR 0.67, 95% CI
0.62–0.73) lower risk of 1-year mortality (p < 0.001) compared to men, after adjusting by age and
number of comorbidities (Table 5).
Table 5. Cox regression survival analysis to assess the risk of 1-year mortality in men and women with
heart failure based on sex, age, and number of comorbidities.
Variable Hazard Ratio a 95% CI b p Value
Sex (Reference: men) 0.672 0.621–0.726 <0.001
Age c (years) 1.077 1.071–1.083 <0.001
Number of comorbidities d 1.057 1.047–1.067 <0.001
a Adjusted by the rest of variables; b 95% confidence interval; c Continuous variable; d Continuous variable,
excluding heart failure.
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4. Discussion
In this population-based study, we analyze the clinical characteristics of 17,516 patients with HF,
and discuss the sex differences observed in their comorbidity, pharmacology, and healthcare utilization.
In our study, women contributed more than men to the total number of patients with HF. We
therefore confirm the results of previous studies reporting a majority of women with HF in the general
population. This would be due to the higher HF prevalence shown by women at advanced ages,
both in the outpatient and hospital setting, that counteracts the initially higher HF incidence and
mortality in men at earlier ages [7,8,23–25]. This was translated into a higher mean age of women in
our study, similar to the results of previous studies that report a 2- to 3-year difference between both
sexes [23,24,26]. Given that age seems to explain some of the differences reported between men and
women with HF [8], we decided to adjust all our study outcomes by age.
One of the most questioned aspects of HF is whether women have a better prognosis than men.
Our results seem to support the hypothesis of a greater survival rate of HF women compared to
men. However, the effect on survival of sex varies depending on the cohort’s characteristics. In the
BADAPIC (Base de Datos de Pacientes con Insuficiencia Cardiaca) study [9], conducted mainly in
Spanish cardiology services, similar mortality rates were found for men and women. Nevertheless,
patients were, on average, 15 years younger, and mostly men (71%). Conde–Martel et al. [23] reported,
in internal medicine services, age-adjusted 1-year mortality rates of 28% and 25% in hospitalized HF
men and women, respectively. In the Olmsted population study, 5-year mortality rates of 59% and 49%
were found in ambulatory men and women [27,28]. In the I-PRESERVE study [29], in hospitalized
patients with preserved left ventricular ejection fraction (LVEF), women presented a 20% lower risk
of death for both cardiovascular and non-cardiovascular events. The MAGGIC meta-analysis [30],
which included information on 41,949 patients, also showed a greater survival of women, suggesting
that lower prevalence of ischemic heart disease, arrhythmias and symphatic activation, and better
ventricular function are protective factors [26,31].
As expected, multimorbidity was the rule rather than the exception in our population, affecting up
to 99% of patients of both sexes. The burden of diseases was considerably similar in men and women,
who presented six or more chronic conditions in 80% of cases, and a median of nine conditions, similar
to that found in other studies [6,24,25,32,33]. Carmona et al. [24] analyzed 198,670 patients, and more
than 60% had five or more non-cardiac comorbidities. This multimorbidity might be justified by the
advanced age of the population with HF, since one in four patients are older than 80 years and tend to
present comorbid diseases [13,33,34]. It has to be highlighted that the high morbidity burden found in
our study could be partially explained by the comprehensive list of chronic diseases analyzed [22].
Some comorbidities presented similar prevalence rates in both sexes. Other chronic conditions
were, however, clearly specific to men or women. Men were more likely to present cardiovascular
comorbidities, such as ischemic heart disease and acute myocardial infarction, cardiac arrhythmia,
cardiomyopathy, peripheral vascular disease, COPD, and chronic renal failure, which is in line with
the results of previous studies [9,12,23,26,32,35]. There are, however, controversies regarding the
effect of sex on the prevalence of chronic renal failure and diabetes, with contradictory results in the
literature [25,32,36–39]. The significant differences shown in COPD prevalence could be associated
with higher levels of tobacco use in men [6,11,25], since toxic habits were clearly more frequent in men
(although probably under-registered), as previously reported in the literature [8,11,26]. On the other
hand, women were more likely to suffer conditions such as depression, osteoporosis, osteoarticular
pathology, varicose veins, hypothyroidism, and asthma. Women also presented a slightly higher BMI,
in agreement with various studies reporting more obesity in women, even tripling that reported in
men in patients over 65 years [4,23,26,31].
The frequent multimorbidity of HF has been translated into more complex pharmacotherapy of
the disease. In fact, over the past two decades, the taking of drugs has increased by more than six
daily [34,35]. This trend is confirmed in our study, in which more than 80% of both men and women
had five or more drugs dispensed. Current HF treatment guidelines are not sex-specific, and we
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therefore recommend the same management of the disease in men and women. However, women have
been historically included in a smaller proportion (around 30%) than men in clinical trials, and their
therapeutic management and prognosis have been less studied. All this leads to a lower prescription
in women of the treatments recommended by clinical practice guidelines [12,31,40–42] and, for reasons
not entirely clear, with lower average drug doses [9,43–45]. Although information on drug doses used
and on the LVEF of our patients were not available in our cohort, we confirmed, in general, the lower
prescription of the specific treatments for HF in women.
Males consumed more drugs for cardiovascular events than women did, which could be justified
by the greater frequency of ischemic heart disease in men [6,41]. The greater combined use of ACE
inhibitors/ARB, beta-blockers, and antialdosteronics could be justified by a higher prevalence of
reduced LVEF in men [41]. In any case, the low use of ACE inhibitors/ARB and BB, which have
been shown to improve the prognosis of the disease, as well as the high consumption of diuretics in
clinically stable patients, is striking. Conde–Martel et al., among others, observed similar diuretics
consumption in both sexes [23,26], whereas in other studies, greater use has been reported in men,
despite women presenting with greater congestion [15,26,40]. The higher prevalence of ischemic
heart disease and arrhythmias in men would justify the greater dispensation of anti-coagulation and
anti-aggregation treatments, in line with the results of Dewan et al. [26], who also found a greater use
of statins [6,41]. In other studies, greater side-effects related to ACE inhibitors have been reported for
women, such as cough or angioedema [5,43,46,47]. In our sample, women had less arrhythmia and
were also treated more frequently with digoxin than with beta-blockers, despite the greater association
in women between use of digoxin and mortality and/or negative adverse effects [12,48,49]. It is worth
highlighting the differences obtained regarding the BADAPIC study [9], conducted in Spain 10 years
earlier. In contrast to our study, no sex differences were observed in the use of diuretics, digitalis, or
anticoagulants. Beta-blockers and ACE inhibitors were dispensed more frequently in men in both
studies, but these drugs were used much more frequently in the BADAPIC study (75% vs. 34% and
82% vs. 33% of men, respectively). These results could be partially explained by the greater presence
of ischemia in BADAPIC patients.
Regarding healthcare use, it is worth noting the much greater use of nursing of women, probably
due to their higher awareness of disease prevention. On the other hand, although the multimorbidity
burden was similar in both sexes, men presented a greater consumption of hospital and specialized
resources than women, which could be explained by the exacerbations and characteristics of their
specific comorbidities, such as ischemic heart disease, arrhythmias, COPD, and chronic renal failure.
In the study by Philibin et al. [16], it was shown that visits to specialties like cardiology were more
frequent in men than in women. Also, in the study of the Olmsted population [27], men with HF
had more annual hospital admissions than women (1.6 vs. 1.2 admissions). We did not study sex
differences in the rate of readmission for HF, which was reported to be greater in women compared to
men in the BADAPIC study, but in those patients referred to specialized HF clinics [9]. In any case,
these data reflect the high fragmentation of care and resource consumption of patients with HF.
The role that the comorbidities and their treatment may play in the prognosis of HF is evidenced
in our study by the high dispensation rates of drugs that could potentially decompensate a stable HF
in both sexes, such as non-steroidal anti-inflammatory drugs, glucocorticoids, and beta-adrenergic
inhalers. As we have seen, HF is, in most cases, accompanied by sex-specific multimorbidity and
polypharmacy, which can potentially result in negative health outcomes due to drug–drug and
drug–disease interactions if it is not correctly managed. This is the reason why person-centered, rather
than disease-centered care is crucial in patients with this condition, in order to know the entire context
of the patient and treat him/her appropriately to improve the prognosis of HF.
The main strength of the study is that we included almost all people with HF in the reference
population from both primary and hospital care, so that men and women were equally represented.
All the variables analyzed regarding comorbidity and healthcare use were extracted from patients’
EHRs. Therefore, this information should be more reliable and accurate than if it had been self-reported
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by patients, although some specific diseases could have potentially been over- or under-reported.
In this regard, data in the EpiChron Cohort undergoes continuous quality control check-ups that
ensure its accuracy and reliability for research purposes. Moreover, we comprehensively analyzed the
comorbidities of HF by using an exhaustive list of chronic conditions, and not only the most prevalent
or severe ones. Regarding HF pharmacology, the information was also reliable as it was obtained from
pharmacy billing records; however, it represented the medications finally dispensed to the patient, and
not all the drugs prescribed by health professionals.
One of the most important limitations of the study corresponds to the lack of data regarding the
LVEF of the patients of the cohort, which was not retrievable from our information sources. We are
aware that the impossibility of differentiating reduced from preserved LVEF HF does not allow us to
analyze the effect of this relevant clinical variable on the assessment of sex differences in the management
and prognosis of HF. Moreover, other relevant variables for the study, such as socioeconomic factors,
were not available in the study cohort, whereas other ones, such as lifestyle habits, were unavailable
(e.g., diet, physical activity) or probably underreported (e.g., smoking and drinking behaviors). Another
major limitation is the cross-sectional nature of the study. We characterized all prevalent cases of HF at
a given time frame, without taking into account the time elapsed since the diagnosis of the disease nor
the chronological appearance of comorbidities over time.
5. Conclusions
This cohort study, based on real-world data of all patients with a diagnosis of HF of a public health
system, confirms clinically relevant differences between men and women regarding their comorbidity
profiles, pharmacological treatment plans, patterns of use of health care services, and prognosis. These
results, that should shortly be replicated to be confirmed in another contexts, may help to orientate the
design of specific strategies for secondary prevention of chronic diseases associated to HF, for the early
detection of specific comorbidities, and for the development of sex-specific clinical guidelines for HF
patients to reduce negative health outcomes and increase the quality of life of this population group.
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